|
- Gemcitabine and oxaliplatin with or without cetuximab in advanced . . .
Methods: In this non-comparative, open-label, randomised phase 2 trial, we recruited patients with locally advanced (non-resectable) or metastatic cholangiocarcinoma, gallbladder carcinoma, or ampullary carcinoma and a WHO performance status of 0 or 1 from 18 hospitals across France and Germany
- ESMO 2022 - First highly-targeted therapy against the . . . - Gustave Roussy
The ReFocus trial led by Gustave Roussy demonstrates the efficacy of a new highly-targeted therapy inhibiting expression of the FGFR 2 gene, which is present in 15–20% of biliary tract cancers
- Prognosis of patients with advanced bile tract carcinoma: assessment . . .
Li SJ et al (2020) Gustave Roussy Immune Score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable early-stage non-small-cell lung cancer: a propensity score matching retrospective cohort study
- Futibatinib: new targeted therapy in intrahepatic cholangiocarcinoma . . .
ReFocus is a first-in-human phase I II trial evaluating RLY-4008 in patients with cholangiocarcinoma and other solid tumors harboring FGFR2 fusion or rearrangement The recommended phase II dose is 70 mg daily The ORR in patients with FGFR inhibitor-naïve patients with FGFR2 fusion-positive cholangiocarcinoma was 73% (n=11)
- First-308: Phase III study of tinengotinib versus physician’s choice in . . .
Exploratory endpoints will assess the correlations between baseline FGFR2 alterations by cfDNA and efficacy, and exposure-response in terms of efficacy and safety Study is open for enrollment Clinical trial information: NCT05948475 Research Sponsor: None
- Investigators Seek to Refocus on FGFR2-altered Cholangiocarcinoma - OncLive
Investigators presented additional preliminary findings from the FGFR2 fusion or rearrangement, FGFR inhibitor-naïve cholangiocarcinoma cohort of the ReFocus trial during the ESMO Congress 2022
- Abstract 4664: MatchR a preclinical platform of models resistant to . . .
At Gustave Roussy, a prospective clinical trial MATCH-R (NCT02517892) is conducted to study the acquired resistance mechanisms and to find new therapeutic approaches for patients
- Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with . . .
Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors
|
|
|